ELIZABETH STOTLAND WEISWASSER is one of the nation’s preeminent life sciences litigators. Co-chair of the Paul, Weiss Litigation Department, Elizabeth specializes in high-stakes patent litigation and strategic counseling for leading pharmaceutical, biotechnology, and medical device companies, combining deep scientific expertise with sophisticated patent law knowledge. She has extensive experience in federal courts and before the U.S. Patent Office in inter partes and post-grant review proceedings. Elizabeth’s practice spans the full range of biopharma technologies, including biologics, small molecules, formulation, drug delivery, and methods of treatment. She also leads teams in related antitrust and commercial litigation matters in the life sciences sector.

Prior to her legal career, Elizabeth earned a B.A. in biochemistry and molecular biology from Northwestern University and conducted graduate studies in molecular biology at Princeton University. Following law school at The University of Chicago, she clerked for Judge Alan D. Lourie of the U.S. Court of Appeals for the Federal Circuit.

Elizabeth has received numerous accolades, including being named “IP Litigator of the Year” by Benchmark Litigation, “New York Litigator of the Year” by Managing Intellectual Property, and “Life Sciences Litigator of the Year” by Euromoney. She has been recognized as one of the 10 “Most Innovative Legal Practitioners” in North America by the Financial Times and is consistently ranked in Chambers USA and Chambers Global for intellectual property, patent, and life sciences. Elizabeth taught biotechnology and life sciences patent law for seven years as an adjunct professor at New York University School of Law. She is actively involved in pro bono work and has been honored by the Legal Aid Society and Westchester Residential Opportunities, where her team received the Harriett Goldberg Fair Housing Award. She has served on the Dean’s Visiting Committee of the University of Chicago Law School and on the boards of Montclair Kimberley Academy and the Epilepsy Foundation.